Phase II trial of imatinib mesylate in patients with metastatic melanoma

K B Kim, O Eton, D W Davis, M L Frazier, D J McConkey, A H Diwan, N E Papadopoulos, A Y Bedikian, L H Camacho, M I Ross, J N Cormier, J E Gershenwald, J E Lee, P F Mansfield, L A Billings, C S Ng, C Charnsangavej, M Bar-Eli, M M Johnson, A J Murgo, V G Prieto, K B Kim, O Eton, D W Davis, M L Frazier, D J McConkey, A H Diwan, N E Papadopoulos, A Y Bedikian, L H Camacho, M I Ross, J N Cormier, J E Gershenwald, J E Lee, P F Mansfield, L A Billings, C S Ng, C Charnsangavej, M Bar-Eli, M M Johnson, A J Murgo, V G Prieto

Abstract

Metastatic melanoma cells express a number of protein tyrosine kinases (PTKs) that are considered to be targets for imatinib. We conducted a phase II trial of imatinib in patients with metastatic melanoma expressing at least one of these PTKs. Twenty-one patients whose tumours expressed at least one PTK (c-kit, platelet-derived growth factor receptors, c-abl, or abl-related gene) were treated with 400 mg of imatinib twice daily. One patient with metastatic acral lentiginous melanoma, containing the highest c-kit expression among all patients, had dramatic improvement on positron emission tomographic scan at 6 weeks and had a partial response lasting 12.8 months. The responder had a substantial increase in tumour and endothelial cell apoptosis at 2 weeks of treatment. Imatinib was fairly well tolerated: no patient required treatment discontinuation because of toxicity. Fatigue and oedema were the only grade 3 or 4 toxicities that occurred in more than 10% of the patients. Imatinib at the studied dose had minimal clinical efficacy as a single-agent therapy for metastatic melanoma. However, based on the characteristics of the responding tumour in our study, clinical activity of imatinib, specifically in patients with melanoma with certain c-kit aberrations, should be examined.

Figures

Figure 1
Figure 1
Clinical and radiological studies of a partial response to imatinib. All metastatic lesions shrank. (A) Response of in-transit metastases on right thigh. (B) Computed tomographic scan showing response of left external iliac lymph node (arrow). (C) Positron emission tomographic scans showing decrease in fluorodeoxyglucose uptake in all lesions (arrows). (D) Photomicrograph of the strong c-kit expression in the tumour of the responder. (E) Photomicrograph of a case of negative c-kit expression.
Figure 2
Figure 2
Tumour and endothelial cell apoptosis before treatment and during the second week of imatinib treatment. (A) Tumour cell apoptosis in five patients; patient 5 had a partial response. (B) Endothelial cell apoptosis in five patients. (C) Photomicrographs of the TUNEL stains for both melanoma and endothelial cells in the responder. Red in the CD31 column represents the endothelial cells, and green in the TUNEL column represents apoptotic cells. Yellow (indicated by an arrow) in the overlay column represents endothelial cells undergoing apoptosis.
Figure 3
Figure 3
Chromatogram of the sequence for the alternative splicing seen in c-kit mRNA from the responding patient. The c-kit cDNA sequence from the responder displayed a deletion of the first three nucleotides of exon 15, which encoded a serine (codon 715).

References

    1. Ashman LK (1999) The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 31: 1037–1051
    1. Barnhill RL, Xiao M, Graves D, Antoniades HN (1996) Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-α receptor, but not the PDGF-β receptor, in human malignant melanoma in vivo. Br J Dermatol 135: 898–904
    1. Beitz JG, Kim IS, Calabresi P, Frackelton Jr AR (1991) Human microvascular endothelial cells express receptors for platelet-derived growth factor. Proc Natl Acad Sci USA 88: 2021–2025
    1. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100–104
    1. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Regenass U, Lydon NB (1995) Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 92: 2558–2562
    1. Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML (2004) A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64: 5913–5919
    1. Crosier PS, Ricciardi ST, Hall LR, Vitas MR, Clark SC, Crosier KE (1993) Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. Blood 82: 1151–1158
    1. Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340–4346
    1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949–954
    1. Druker BJ, Lydon NB (2000) Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3–7
    1. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342–4349
    1. Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, Fidler IJ (2003) Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 9: 6534–6544
    1. Lasota J, Kopczynski J, Majidi M, Miettinen M, Sarlomo-Rikala M (2002) Apparent KIT Ser(715) deletion in GIST mRNA is not detectable in genomic DNA and represents a previously known splice variant of KIT transcript. Am J Pathol 161: 739–741
    1. Mathew P, Fidler IJ, Logothetis CJ (2004) Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol 31: 24–29
    1. Okuda K, Weisberg E, Gilliland DG, Griffin JD (2001) ARG tyrosine kinase activity is inhibited by STI571. Blood 97: 2440–2448
    1. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, Ostman A (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62: 5476–5484
    1. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289: 1938–1942
    1. Shen SS, Zhang PS, Eton O, Prieto VG (2003) Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 30: 539–547
    1. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1–10
    1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205–216
    1. Ugurel S, Hildenbrand R, Zimpfer A, La Rosee P, Paschka P, Sucker A, Keikavoussi P, Becker JC, Rittgen W, Hochhaus A, Schadendorf D (2005) Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92: 1398–1405
    1. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358: 1421–1423
    1. Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, Brown M, Nielsen OS (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39: 2006–2011
    1. Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA (2006) Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106: 2005–2011

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren